Express News | JMP Securities Reiterates Market Outperform on Rallybio, Maintains $8 Price Target

Moomoo 24/7Apr 18 13:18 ET

Rallybio Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/18/2024 346.93% JMP Securities → $8 Reiterates Market Outperform → Market Outperform 04/11/2024 514.53%

BenzingaApr 18 13:17 ET

Buy Rating Affirmed for Rallybio Amid Significant Market Opportunity in FNAIT Treatment

TipRanksApr 17 19:15 ET

Rallybio Corporation Announces FNAIT Systematic Literature Review And Meta-Analysis Presented At The Academy Of Managed Care Pharmacy 2024 Annual Meeting

- Data Support HPA-1a Negative Frequency of More than 2% in Nearly 200,000 Screened Pregnant Women -- Among HPA-1a Negative Pregnant Women, Approximately 33% are at Higher Risk for Alloimmunization -R

BenzingaApr 17 16:08 ET

12 Health Care Stocks Moving In Monday's Intraday Session

GainersLongeveron (NASDAQ:LGVN) stock moved upwards by 44.4% to $2.44 during Monday's regular session. The market value of their outstanding shares is at $7.7 million. Mobile-health Network (NASDAQ:MN

BenzingaApr 15 12:31 ET

Marinus Pharmaceuticals, Cartesian Therapeutics, Adial Pharmaceuticals Among Healthcare Movers

Seeking AlphaApr 15 10:00 ET